William Blair Comments on Glaukos' Q4 Earnings (NYSE:GKOS)

Glaukos Co. (NYSE:GKOS - Free Report) - Investment analysts at William Blair raised their Q4 2024 earnings per share (EPS) estimates for shares of Glaukos in a research note issued on Tuesday, November 5th. William Blair analyst M. Andrew now forecasts that the medical instruments supplier will earn ($0.34) per share for the quarter, up from their prior forecast of ($0.36). The consensus estimate for Glaukos' current full-year earnings is ($2.16) per share. William Blair also issued estimates for Glaukos' Q1 2025 earnings at ($0.33) EPS, Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($1.05) EPS.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.20. The business had revenue of $96.70 million during the quarter, compared to the consensus estimate of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 20.28%. The firm's quarterly revenue was up 23.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.50) earnings per share.

A number of other analysts also recently issued reports on GKOS. StockNews.com raised Glaukos from a "sell" rating to a "hold" rating in a research report on Monday, October 21st. Needham & Company LLC lifted their price objective on Glaukos from $131.00 to $137.00 and gave the stock a "buy" rating in a report on Thursday, August 1st. Truist Financial boosted their price objective on Glaukos from $145.00 to $152.00 and gave the company a "buy" rating in a research note on Monday, October 14th. Wells Fargo & Company increased their target price on shares of Glaukos from $135.00 to $145.00 and gave the stock an "overweight" rating in a research report on Tuesday. Finally, Piper Sandler set a $140.00 target price on shares of Glaukos in a research note on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $134.55.

Glaukos Stock Performance

Shares of NYSE:GKOS traded up $2.56 during mid-day trading on Friday, reaching $141.89. The company had a trading volume of 681,591 shares, compared to its average volume of 580,850. Glaukos has a one year low of $59.22 and a one year high of $143.58. The company has a current ratio of 5.48, a quick ratio of 4.67 and a debt-to-equity ratio of 0.19. The company's 50-day moving average price is $129.89 and its 200-day moving average price is $120.77. The firm has a market cap of $7.82 billion, a price-to-earnings ratio of -46.98 and a beta of 1.02.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GKOS. Point72 Asset Management L.P. bought a new stake in Glaukos during the second quarter worth about $67,460,000. Primecap Management Co. CA raised its holdings in shares of Glaukos by 43.9% during the 2nd quarter. Primecap Management Co. CA now owns 1,220,815 shares of the medical instruments supplier's stock valued at $144,483,000 after buying an additional 372,180 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in Glaukos by 148.3% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 412,376 shares of the medical instruments supplier's stock worth $48,805,000 after buying an additional 246,322 shares during the last quarter. Iron Triangle Partners LP boosted its stake in Glaukos by 75.6% in the first quarter. Iron Triangle Partners LP now owns 429,525 shares of the medical instruments supplier's stock worth $40,500,000 after buying an additional 184,919 shares in the last quarter. Finally, Driehaus Capital Management LLC boosted its stake in Glaukos by 24.0% in the second quarter. Driehaus Capital Management LLC now owns 803,650 shares of the medical instruments supplier's stock worth $95,112,000 after buying an additional 155,653 shares in the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Glaukos

In other news, Director Marc Stapley sold 6,250 shares of the company's stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $125.93, for a total value of $787,062.50. Following the transaction, the director now owns 34,076 shares of the company's stock, valued at approximately $4,291,190.68. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Glaukos news, COO Joseph E. Gilliam sold 5,000 shares of the business's stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $129.36, for a total value of $646,800.00. Following the completion of the transaction, the chief operating officer now owns 102,169 shares of the company's stock, valued at $13,216,581.84. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Marc Stapley sold 6,250 shares of the firm's stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $125.93, for a total transaction of $787,062.50. Following the sale, the director now owns 34,076 shares in the company, valued at approximately $4,291,190.68. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 16,525 shares of company stock valued at $2,142,029 in the last three months. Company insiders own 6.40% of the company's stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.